GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 7,218,628 shares, a decrease of 33.7% from the May 14th total of 10,887,679 shares. Based on an average daily trading volume, of 1,769,530 shares, the short-interest ratio is currently 4.1 days. Currently, 2.2% of the company’s stock are short sold.

GoodRx Trading Up 3.0%

NASDAQ GDRX opened at $2.73 on Tuesday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The stock has a market capitalization of $935.22 million, a PE ratio of 45.51, a price-to-earnings-growth ratio of 1.23 and a beta of 1.61. The firm has a 50 day moving average of $2.52 and a two-hundred day moving average of $2.48.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company had revenue of $194.01 million during the quarter, compared to analysts’ expectations of $185.40 million. During the same quarter in the previous year, the business posted $0.09 EPS. The firm’s revenue was down 4.4% on a year-over-year basis. As a group, research analysts expect that GoodRx will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

GDRX has been the topic of several recent research reports. Mizuho cut their target price on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Friday, February 27th. Citigroup upped their target price on shares of GoodRx from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Wells Fargo & Company cut their target price on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $3.50 target price on shares of GoodRx in a research note on Friday, May 8th. Finally, Weiss Ratings downgraded shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 20th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Essential Partners LLC grew its holdings in GoodRx by 375.4% during the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after acquiring an additional 11,295 shares in the last quarter. Meridian Wealth Management LLC acquired a new position in GoodRx during the 4th quarter worth approximately $29,000. SG Americas Securities LLC acquired a new position in GoodRx during the 1st quarter worth approximately $29,000. Krilogy Financial LLC acquired a new position in GoodRx during the 1st quarter worth approximately $33,000. Finally, Quarry LP acquired a new position in GoodRx during the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.